Whalegun
Lobbying

Currax Pharmaceuticals's latest lobbying report covers Q2 2026, at $50K. The four quarters Q3 2025–Q2 2026 total $200K. Its first report covers Q2 2023; the issues it reports most are Pharmacy.

Currax Pharmaceuticals

Latest quarter
$50K
Q2 2026 · 1 reports
Last 12 months
$200K
Last 4 quarters
vs last quarter
0.0%
Q2 2026 against the quarter before
First report
Q2 2023
The first quarter a report named it

Lobbying by quarter

Currax Pharmaceuticals lobbying by quarter
Currax Pharmaceuticals lobbying by quarter
QuarterAmountReports
Q2 2023$50K1
Q3 2023$90K1
Q4 2023$90K1
Q1 2024$90K1
Q2 2024$90K1
Q3 2024$90K1
Q4 2024$70K1
Q1 2025$60K1
Q2 2025$50K1
Q3 2025$50K1
Q4 2025$50K1
Q1 2026$50K1
Q2 2026$50K1

Policy issues the reports name

  • Pharmacy13 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES13 reports
  • SENATE13 reports
  • Centers For Medicare and Medicaid Services (CMS)4 reports
  • Executive Office of the President (EOP)4 reports
  • Health & Human Services, Dept of (HHS)4 reports

Firms it paid

Firm
Dla Piper$880K13 quarters

Former officials lobbying for it

Former position
MARGARET MARTINSenior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard BurrQ1 2025

Lobbying reports

Filed by
07/20for Q2Dla Piper$50K
04/20for Q1Dla Piper$50K
01/20for Q4 2025Dla Piper$50K
25/10/20for Q3 2025Dla Piper$50K
25/07/21for Q2 2025Dla Piper$50K
25/04/21for Q1 2025Dla Piper$60K
25/01/21for Q4 2024Dla Piper$70K
24/10/21for Q3 2024Dla Piper$90K
24/07/22for Q2 2024Dla Piper$90K
24/04/19for Q1 2024Dla Piper$90K
24/01/22for Q4 2023Dla Piper$90K
23/10/20for Q3 2023Dla Piper$90K
23/08/31for Q2 2023Dla Piper$50K
23/08/30for Q2 2023Dla PiperUnder $5,000